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pleural metastases/effusion, normal serum hemoglobin, CRP, 
LDH and albumin (surrogate markers of disease extent), early 
PRT within 6 months from diagnosis of metastases, age <65 
years, and good performance status (ECOG PS). Biological 
subtype (Her2 and hormone receptors), comorbidity and 
reirradiation to a previously treated volume did not correlate 
with fractionation. Rate of LC PRT remained unchanged over 
time. In line with imbalances in prognostic factors, survival 
was significantly longer after LC PRT in univariate analysis. 
However, after correcting imbalances in multivariate analysis 
no survival difference was found. Prognosis was influenced by 
biological subtype (worse for triple negative status), 
extraskeletal disease extent, presence of anemia and 
abnormal CRP. Even patients with PS3 had median survival of 
3 months, which indicates that they life long enough to 
experience clinical benefit after PRT.  
 
Conclusion: The likelihood of receiving LC PRT was 
significantly higher in younger patients, those with good PS, 
limited disease extent, and shorter time interval after 
diagnosis of metastatic disease. Educating physicians about 
these factors might contribute to optimal resource 
utilization. The limited need for reirradiation after single 
fraction PRT might encourage physicians to prescribe this 
convenient regimen, which is also suitable for PS3 patients.  
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Purpose or Objective: To evaluate the efficacy of 
hypofractionated radiotherapy (16 Gy in 2 fractions one week 
apart) in pain relief in patients with complicated bone 
metastases and poor performance status. 
 
Material and Methods: This was a phase 2 multicenter study 
of patients with complicated bone metastases and Karnofsky 
performance status from 30 to 60 who underwent 2 fractions 
of radiotherapy with 8 Gy each one week apart. Pain 
response and quality of life (QOL) were measured using the 
International Consensus on Palliative Radiotherapy Endpoints 
and EORTC QOL Pal 15 and BM 22 questionnaires. Complete 
response was defined as a pain score of 0 at treated site with 
no concomitant increase in daily oral morphine equivalent 
(OMED). Partial response was defined as pain reduction of 2 
or more on a scale of 0 to 10 scales without analgesic 
increase, or analgesic reduction of 25% or more from baseline 
without an increase in pain. Pain progression as an increase 
in pain score of 2 or more above baseline with stable OMED, 
or an increase of 25% or more in OMED compared with 
baseline with the pain score stable or 1 point above baseline, 
and others were indeterminate. The study was registered on 
clinicaltrial.gov (NCT02376322) 
 
Results: Thirty patients were enrolled from 4 centres in 
Brazil, Italy and Canada during July 2014 to September 2015. 
There were 14 male and 16 female patients. The median age 
was 58 years old (range 26 - 79). Twenty-two (73%) had 
extraosseous soft tissue component, 4 neuropathic pain, 2 
post-surgical intervention, and 2 impending fracture in 
weight bearing bone. The most common primary cancer sites 
were breast (n = 7) and lung/prostate (n = 4 each). The most 
commonly irradiated areas were lumbosacral spine (n = 10), 
pelvis/hips (n = 8), thoracic spine (n = 7), cervical spine (n = 
3), and superficial bones (n = 2). The median pre-treatment 
worst pain score was 8 (range 1 to 10) and the median daily 
OMED was 40 mg (range 0 to 360). The median follow up was 
3.7 months (range 0.3 to 9.6). At 2 months, 20 patients were 
alive (66%). Eleven (55%) had complete or partial response, 4 
(20%) progressive disease and 5 (25%) indeterminate 
response. A statistically significant improvement (p < 0.0001) 
was seen in the painful sites and physical functioning for the 
BM22 while the other items in BM 22 and C15-PAL remained 
stable. No patient suffered from spinal cord compression or 
pathologic fracture, and re-irradiation was not required. 
 
Conclusion: The 2 fractions of radiotherapy with 8 Gy each 
one week apart appears to be well tolerated without serious 
side effects in patients with complicated bone metastases 
and poor performance status. QOL remained stable. The 
efficacy was similar in patients with uncomplicated bone 
metastases treated with hypofractionated radiotherapy. 
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Purpose or Objective: The aim of this phase II study was to 
evaluate the symptomatic response rate of short course 
radiation therapy (SCRT) in patients with advanced rectal 
cancer not amenable for curative treatment and with 
obstructive symptoms. 
 
Material and Methods: Patients unfit for surgical resection 
due to synchronous metastases, age and/or comorbidities, 
were eligible. The sample size was calculated based on the 
two-stage design by Simon. SCRT was delivered with an 
isocentric four-field box technique (total dose: 25 Gy; 5 Gy 
per fraction in 5 days). No chemotherapy was allowed during 
SCRT. Clinical outcome measures were symptomatic response 
rate, toxicity, colostomy-free survival and overall survival. 
 
Results: From October 2003 to November 2012, 18 patients (4 
females and 14 males; mean age 77.5 years) were enrolled. 
The median follow up was 57 months (range: 23-132 months). 
Symptomatic response was: 5.5% no change, 66.7 % partial 
response, 27.8% complete response. No patients stopped 
treatment for gastrointestinal or genitourinary toxicities: 
27.8% patients had grade 1-2 toxicity and 16.7% had grade 3 
toxicity; only 1 patient had haematological grade 2 toxicity. 
One and 2-year colostomy-free survival were 100% and 71.4% 
(median: 30 months), respectively. Reduction/resolution of 
pain and bleeding was 87.5 % and 100 %, respectively. One 
and 2-year actuarial overall survival were 66.3% and 53% 
(median: 25 months), respectively. 
 
Conclusion: In this phase II study based on SCRT in patients 
with symptomatic rectal cancer not eligible for curative 
treatment an improvement of initial symptoms with 
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acceptable incidence of side effects was recorded. 
Furthermore, it was possible to avoid colostomy in a 
significant proportion of patients. 
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Purpose or Objective: To define the Maximum Tolerated 
Dose (MTD) of Middle Half Body (MHB) Radiotherapy (RT) 
delivered with a conformal 3D technique and twice daily 
fractionation in prostate cancer (PC) multiple bone 
metastases. 
 
Material and Methods: A phase I trial was designed with two 
level of dose: 13 Gy (3.25Gy per fraction) and 15 Gy (3.75 Gy 
per fraction). Eligibility criteria were: histological confirmed 
PC, symptomatic and or impending for fracture multiple bone 
metastases, ECOG performance status 0-4, expected survival 
>3 months, and adequate bone marrow function. 
Radiotherapy was delivered using a 3D conformal technique 
twice daily in 2 sequential days, with at least 8 hours interval 
between fractions. Cohort of 6-12 patients were recruited in 
order to define the MTD (any acute toxicity > grade 3 of 
RTOG scale). Pain and quality of life were recorded using 
analogue-visual scales (VAS and CLAS). Clinical target volume 
was defined as pelvic bones, involved femurs + lumbar spine. 
Planning target volume was defined as the CTV + 1 cm. 
 
Results: From June 2010 to November 2014, 22 patients 
(median age 73 years; range 58-86) were enrolled. In Figure 1 
treatment volumes are described. 
 
 
 
At diagnosis, all patients (100%) reported pain. Clinical pain 
remission (complete or partial) was observed in 95% of 
patients. Six patients (27.3%) had a complete symptoms 
resolution and 15 (68.2%) had a partial symptom control. Pain 
worsening after radiation treatment was recorded only in 1 
patient. On the basis of analogue-visual scales a significant 
decrease of pain was recorded (mean VAS pre RT versus post 
RT: 4.6 versus 3,0; p=0.034; mean pain score pre RT versus 
post RT: 3.1 versus 1,9; p=0.069; mean drug score pre RT 
versus post RT: 3.9 versus 2,5; p=0.088). Skin and 
gastrointestinal acute toxicities were only grade 1-2. With a 
median follow up of 6 months (range 1-26) no late toxicity 
was recorded. 
 
Conclusion: An accelerated MHB RT treatment with twice 
daily fraction on bone metastases from PC was well tolerated 
up to 15 Gy. A phase II study is ongoing to confirm efficacy on 
pain control and quality of life. 
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Purpose or Objective: To evaluate the factors associated 
with treatment response (relieve of SVCS) and overall 
survival. 
 
Material and Methods: Thirty one patients with SVCS 
between 2012-2015 were analyzed. The end points were: 
overall survival and SVCS resolution. SVCS resolution was 
determined as the absence of symptoms related to the 
compression of superior vena cava. The variables tested 
were: sex (male vs female), age (<50 years vs > 50 years), 
primary site (lung vs others), KPS (<70 vs >/= 70), previous 
palliative RT (no vs yes), BED Gy10 dose (<25 vs > 25), more 
than 1 year of the initial diagnosis (no vs yes), tumor size 
(<10 cm vs >/= 10 cm), and number of previous 
chemotherapy (CT) lines (0 or 1 vs 2 or more), presence of: 
bone mets (no vs yes), central nervous system (SNC) mets (no 
vs yes), lung mets (no vs yes), liver mets (no vs yes), lymph 
node mets (no vs yes) and SVCS resolution (no vs yes). 
 
Results: The mean follow-up time of the patients alive was 
376 days (median 241 days). The 6-months and 1-year OS 
survival were 31.5 % and 18 %, respectively. Factors 
influencing positively the survival in univariate analysis were: 
KPS >/= 70 (p=0.001), 0 or 1 previous CT lines (p=0.012), 
diagnosis <1y (p=0.007), no bone mets (p=0.010), no lung 
mets (p=0.011), no liver mets (p=0.031) and SVCS resolution 
(p<0.001). In multivariate analysis only SVCS resolution 
(p=0.005) remained significant and no lung metastasis was 
marginally related (p=0.060). The overall SVCS resolution 
rate was 84% (12/25 cases). Nineteen patient were treated 
with radiotherapy (RT), four patient with chemotherapy and 
2 patients with RT + CT. Six cases receive no treatment (3 
because of extremely low KPS and 3 because of the risks of 
re-irradiation) and were excluded from the efficacy and 
multifactorial analysis. None of the variables tested 
influenced the treatment response rate. 
 
Conclusion: Treatment response rate was more than 80 % 
and it was the strongest factor associated with overall 
survival. This fact encourages the indication of treatment 
even in patients with low performance status or previous 
cervico-thoracic radiotherapy, after a risk-benefit analysis. 
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Purpose or Objective: The aim of this analysis was to 
determine the risk of vertebral compression fracture (VCF) 
following spine radiotherapy (RT) specific to colorectal 
cancer (CRC) spinal metastases, and to determine clinical 
predictors 
 
Material and Methods: We retrospectively reviewed 267 
spinal segments (176 metastatic and 91 non-metastatic 
vertebras) in 66 patients, which were irradiated for pain 
palliation between 2007 and 2014. The primary endpoint was 
development of a VCF following RT, either a de novo VCF or 
